Other Clinical Trial - Measuring Corneal Cells With Specular Microscopy

Status Completed

Clinical Trial Summary

Assess changes in the corneal cell count using Specular Microscopy following tretments with Anti-VEGF injections

Clinical Trial Description

Patients with active Wet AMD often receive intraocular Anti-VEGF injections such as Macugen, Lucentis and Avastin on a monthly basis for an extended period of time. While these medications are very effective at controlling the Choroidal Neovascularization associated with this disease, the impact of monthly intravigtreal Anti-VEGF injections on the viability of corneal endothelial cells has yet to be fully characterized. The availability of CESM as a diagnostic test that can be performed quickly and painlessly in the clinic offers a method of tracking corneal endothelial cell count in this patient population. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

Retinal Diseases

Clinical Trial Details

NCT number	NCT01792154
Study type	Observational
Source	Retina Institute of Hawaii
Contact
Status	Completed
Phase	N/A
Start date	August 2012
Completion date	November 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04968756` - Evaluating the Safety of the SPECTRALIS CENTAURUS Device	N/A
Recruiting	`NCT01521065` - An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration	Phase 2
Completed	`NCT00437593` - UHR-OCT and HD-OCT for Preretinal Membranes: ICG Versus Membrane Blue	N/A
Completed	`NCT04919473` - Dose-Escalation Study to Evaluate the Safety and Tolerability of Intravitreal vMCO-I in Patients With Advanced Retinitis Pigmentosa	Phase 1/Phase 2
Terminated	`NCT01225146` - Study of 2.0 mg Ranibizumab in Subjects With Ischemic Central Retinal Vein Occlusion (RAVE2)	Phase 1
Completed	`NCT01205035` - High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia	Phase 2
Completed	`NCT00812760` - Effect of Levodopa on Human Multifocal Electroretinogram	Phase 4
Active, not recruiting	`NCT06071546` - Clinical Investigation of a New Version of MAIA Microperimeter on Healthy Subjects and Patients With Retinal Pathology	N/A
Completed	`NCT02946879` - Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)
Completed	`NCT01016873` - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD	Phase 2
Recruiting	`NCT04592068` - AI Classifies Multi-Retinal Diseases
Completed	`NCT01746563` - Intravitreal Ranibizumab Combined With Panretinal Photocoagulation in Patients With Proliferative Diabetic Retinopathy	Phase 1/Phase 2
Completed	`NCT01399515` - Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa	Phase 2
Terminated	`NCT02348359` - X-82 to Treat Age-related Macular Degeneration	Phase 2
Completed	`NCT03954626` - Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD	Phase 3
Completed	`NCT02582164` - Long-Working Distance OCT for Children	N/A
Completed	`NCT01790958` - Microcurrent Stimulation to Treat Macular Degeneration	N/A
Recruiting	`NCT05283941` - Pistachios and Neural Macular Pigment	N/A
Completed	`NCT04678375` - Artificial Intelligence for Detecting Retinal Diseases
Completed	`NCT04902170` - Long-shaft Vitrectomy Probe in Highly Myopic Eyes	N/A